Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2016, provides an overview of the Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline landscape.

Oral herpes is an infection of the lips, mouth, or gums due to the herpes simplex virus. Oral herpes is also called herpes labialis. Symptoms include sore throat, fever, swollen glands and painful swallowing. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Herpes Labialis (Oral Herpes).

Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Herpes Labialis (Oral Herpes) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Herpes Labialis (Oral Herpes) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Herpes Labialis (Oral Herpes) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Labialis (Oral Herpes) (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Herpes Labialis (Oral Herpes) Overview 7
Therapeutics Development 8
Pipeline Products for Herpes Labialis (Oral Herpes) - Overview 8
Pipeline Products for Herpes Labialis (Oral Herpes) - Comparative Analysis 9
Herpes Labialis (Oral Herpes) - Therapeutics under Development by Companies 10
Herpes Labialis (Oral Herpes) - Therapeutics under Investigation by Universities/Institutes 11
Herpes Labialis (Oral Herpes) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Herpes Labialis (Oral Herpes) - Products under Development by Companies 15
Herpes Labialis (Oral Herpes) - Products under Investigation by Universities/Institutes 16
Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development 17
AiCuris GmbH and Co KG 17
Beech Tree Labs, Inc. 18
Foamix Pharmaceuticals Ltd. 19
Mymetics Corporation 20
NanoViricides, Inc. 21
Onxeo SA 22
Shulov Innovative Science Ltd. 23
TGV-Laboratories 24
Vironova AB 25
Herpes Labialis (Oral Herpes) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
acyclovir - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
acyclovir - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Aspidasept - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
B-220 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
BTL-TMLHSV - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
herpes simplex virus [type 1, 2] (virus like particle) vaccine - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
herpes simplex virus [type 1, 2] vaccine - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
pritelivir - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecule for Cold Sores - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Teg-379 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ZEP-3 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Herpes Labialis (Oral Herpes) - Dormant Projects 49
Herpes Labialis (Oral Herpes) - Discontinued Products 50
Herpes Labialis (Oral Herpes) - Product Development Milestones 51
Featured News & Press Releases 51
Feb 16, 2016: Cipher Pharmaceuticals announces Sitavig accepted for review by Health Canada 51
Jul 21, 2014: BioAlliance Pharma announces the launch of Sitavig in the United States by its partner Innocutis and the granting of a new U.S. Sitavig patent 51
Jul 10, 2013: BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants 52
May 27, 2013: BioAlliance Pharma Presents Results Of Sitavig At 10th EADV Symposium 52
Apr 15, 2013: BioAlliance Pharma's Sitavig Receives US Marketing Authorization For Treatment Of Herpes Labialis 53
Apr 04, 2013: Beech Tree Labs Successfully Completes IND Phase I/IIa Oral Herpes Clinical Trial 54
Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig 54
May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier 55
Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure 55
Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis 56
Nov 17, 2010: BioAlliance Pharma Presents Pharmacokinetic Results Of Sitavir At AAPS Annual Meeting 56
Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress 57
Sep 14, 2010: Beech Tree Labs Initiates Phase I/IIa Oral Herpes Trial 57
Sep 07, 2010: BioAlliance Pharma Receives European Patent For Acyclovir Lauriad 58
Aug 26, 2010: BioAlliance Pharma Plans To Submit Acyclovir Lauriad NDA 58

Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

List of Tables

Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2016 8
Number of Products under Development for Herpes Labialis (Oral Herpes) - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Herpes Labialis (Oral Herpes) - Pipeline by AiCuris GmbH and Co KG, H2 2016 17
Herpes Labialis (Oral Herpes) - Pipeline by Beech Tree Labs, Inc., H2 2016 18
Herpes Labialis (Oral Herpes) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 19
Herpes Labialis (Oral Herpes) - Pipeline by Mymetics Corporation, H2 2016 20
Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides, Inc., H2 2016 21
Herpes Labialis (Oral Herpes) - Pipeline by Onxeo SA, H2 2016 22
Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd., H2 2016 23
Herpes Labialis (Oral Herpes) - Pipeline by TGV-Laboratories, H2 2016 24
Herpes Labialis (Oral Herpes) - Pipeline by Vironova AB, H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 32
Number of Products by Stage and Molecule Type, H2 2016 34
Herpes Labialis (Oral Herpes) - Dormant Projects, H2 2016 49
Herpes Labialis (Oral Herpes) - Discontinued Products, H2 2016 50